Survival with Optune + TMZ vs TMZ alone was significantly higher at the 2-year landmarkanalysis and remained higher at 5 years1,2
Median OS was significantly extended with Optune—by nearly 5 months (P<0.001)1
Optune + TMZ also significantly improved PFS vs TMZ alone1
- Median PFS: 6.7 months vs 4.0 months (P<0.001)
More time on Optune predicted increased significant survival benefit4
*Based on the amount of time Optune was turned on and providing therapy over the course of a month. These data reflect the average patient usage of Optune for the first 6 months of treatment (months 1-6).5
† Approximation, based on percentage of usage.
‡ vs TMZ alone.
- Monthly usage was a predictor of survival benefit, independent of other prognostic factors such as KPS, age, or MGMT methylation status4
of patients received a survivalbenefit from Optune because they used it more than half the time (n=388/450)4
Long-term use is supported by strong evidence
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers now include alternating electric field therapy (Optune) in combination with temozolomide (TMZ) following maximal safe resection and standard brain radiation therapy with concurrent TMZ as Category 1 recommended treatment option for patients with newly diagnosed supratentorial glioblastoma (GBM) and good performance status.* There is uniform NCCN consensus for this recommendation based on high-level evidence (Category 1).
*The NCCN defines good performance as Karnofsky Performance Score (KPS) ≥60. The trial for which the IFU is based used an eligibility criteria of KPS ≥70.2,6
MGMT, O-6-methylguanine—DNA methyltransferase; OS, overall survival; PFS, progression-free survival.
The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
References: 1. Optune. Instructions for Use for Glioblastoma Multiforme. Novocure; 2019. 2. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306-2316. 3. Stupp R, Idbaih A, Steinberg DM, et al. Prospective, multi-center phase III trial of tumor treating fields together with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. Presented at: 2017 Annual Meeting of the American Association for Cancer Research; April 1-5, 2017; Washington, DC. Oral presentation LBA AACR CT007. 4. Toms SA, Kim CY, Nicholas G, Ram Z. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. J Neurooncol. 2019;141(2):467-473. 5. Novocure Data on File OPT-135. 6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers. V.3.2020. © 2020 National Comprehensive Cancer Network, Inc. All rights reserved. Accessed December 7, 2020. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.